tiprankstipranks
Medtronic (MDT)
NYSE:MDT
US Market

Medtronic (MDT) Stock Forecast & Price Target

6,454 Followers
See the Price Targets and Ratings of:

MDT Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
11 Buy
7 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Medtronic
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDT Stock 12 Month Forecast

Average Price Target

$109.80
▲(26.75% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Medtronic in the last 3 months. The average price target is $109.80 with a high forecast of $125.00 and a low forecast of $86.00. The average price target represents a 26.75% change from the last price of $86.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"79":"$79","126":"$126","90.75":"$90.8","102.5":"$102.5","114.25":"$114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$109.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$86.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[79,90.75,102.5,114.25,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,89.05538461538461,92.05076923076923,95.04615384615384,98.04153846153847,101.03692307692307,104.0323076923077,107.0276923076923,110.02307692307693,113.01846153846154,116.01384615384616,119.00923076923077,122.00461538461539,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,87.88615384615385,89.71230769230769,91.53846153846155,93.36461538461539,95.19076923076923,97.01692307692308,98.84307692307692,100.66923076923077,102.49538461538461,104.32153846153847,106.14769230769231,107.97384615384615,{"y":109.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,86.06,86.05538461538461,86.05076923076923,86.04615384615384,86.04153846153847,86.03692307692307,86.0323076923077,86.0276923076923,86.02307692307693,86.01846153846154,86.01384615384616,86.00923076923077,86.00461538461539,{"y":86,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":85.764,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.986,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.307,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.698,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.355,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.308,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.754,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.282,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.878,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.305,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$125.00Average Price Target$109.80Lowest Price Target$86.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital
$118
Buy
36.21%
Upside
Reiterated
04/02/26
Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)
Wells Fargo Analyst forecast on MDT
Wells Fargo
Wells Fargo
$114
Buy
31.59%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Medtronic (MDT)
Barclays Analyst forecast on MDT
Barclays
Barclays
$118$120
Buy
38.52%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Apellis Pharmaceuticals (NASDAQ: APLS)
William Blair Analyst forecast on MDT
William Blair
William Blair
$86
Buy
-0.73%
Downside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
Piper Sandler Analyst forecast on MDT
Piper Sandler
Piper Sandler
$105$91
Hold
5.04%
Upside
Reiterated
04/01/26
Piper Sandler Keeps Their Hold Rating on Medtronic (MDT)
TD Cowen
$119
Buy
37.37%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), AbSci (NASDAQ: ABSI) and Medtronic (NYSE: MDT)
Needham
$120
Buy
38.52%
Upside
Assigned
03/26/26
Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
Bank of America Securities Analyst forecast on MDT
Bank of America Securities
Bank of America Securities
$110
Buy
26.98%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), ARS Pharmaceuticals (NASDAQ: SPRY) and CG Oncology, Inc. (NASDAQ: CGON)
DBS
$90
Hold
3.89%
Upside
Reiterated
03/18/26
Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (NASDAQ: TRVI), Annexon Biosciences (NASDAQ: ANNX) and Medtronic (NYSE: MDT)
Truist Financial Analyst forecast on MDT
Truist Financial
Truist Financial
Hold
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Citi
$117
Buy
35.06%
Upside
Reiterated
03/11/26
Medtronic (MDT) Receives a Buy from Citi
Mizuho Securities Analyst forecast on MDT
Mizuho Securities
Mizuho Securities
$125
Buy
44.29%
Upside
Initiated
02/18/26
Medtronic resumed with an Outperform at MizuhoMedtronic resumed with an Outperform at Mizuho
Robert W. Baird Analyst forecast on MDT
Robert W. Baird
Robert W. Baird
$103$100
Hold
15.43%
Upside
Reiterated
02/18/26
Medtronic price target lowered to $100 from $103 at BairdMedtronic price target lowered to $100 from $103 at Baird
Bernstein Analyst forecast on MDT
Bernstein
Bernstein
$112
Buy
29.29%
Upside
Reiterated
02/18/26
Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)
BTIG
Hold
Reiterated
02/18/26
BTIG Sticks to Its Hold Rating for Medtronic (MDT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital
$118
Buy
36.21%
Upside
Reiterated
04/02/26
Analysts Are Bullish on Top Healthcare Stocks: Medtronic (MDT), Pharvaris (PHVS)
Wells Fargo Analyst forecast on MDT
Wells Fargo
Wells Fargo
$114
Buy
31.59%
Upside
Assigned
04/02/26
Wells Fargo Reaffirms Their Buy Rating on Medtronic (MDT)
Barclays Analyst forecast on MDT
Barclays
Barclays
$118$120
Buy
38.52%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Apellis Pharmaceuticals (NASDAQ: APLS)
William Blair Analyst forecast on MDT
William Blair
William Blair
$86
Buy
-0.73%
Downside
Assigned
04/01/26
Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (NASDAQ: SRRK) and Medtronic (NYSE: MDT)
Piper Sandler Analyst forecast on MDT
Piper Sandler
Piper Sandler
$105$91
Hold
5.04%
Upside
Reiterated
04/01/26
Piper Sandler Keeps Their Hold Rating on Medtronic (MDT)
TD Cowen
$119
Buy
37.37%
Upside
Assigned
03/26/26
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), AbSci (NASDAQ: ABSI) and Medtronic (NYSE: MDT)
Needham
$120
Buy
38.52%
Upside
Assigned
03/26/26
Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact
Bank of America Securities Analyst forecast on MDT
Bank of America Securities
Bank of America Securities
$110
Buy
26.98%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT), ARS Pharmaceuticals (NASDAQ: SPRY) and CG Oncology, Inc. (NASDAQ: CGON)
DBS
$90
Hold
3.89%
Upside
Reiterated
03/18/26
Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (NASDAQ: TRVI), Annexon Biosciences (NASDAQ: ANNX) and Medtronic (NYSE: MDT)
Truist Financial Analyst forecast on MDT
Truist Financial
Truist Financial
Hold
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Citi
$117
Buy
35.06%
Upside
Reiterated
03/11/26
Medtronic (MDT) Receives a Buy from Citi
Mizuho Securities Analyst forecast on MDT
Mizuho Securities
Mizuho Securities
$125
Buy
44.29%
Upside
Initiated
02/18/26
Medtronic resumed with an Outperform at MizuhoMedtronic resumed with an Outperform at Mizuho
Robert W. Baird Analyst forecast on MDT
Robert W. Baird
Robert W. Baird
$103$100
Hold
15.43%
Upside
Reiterated
02/18/26
Medtronic price target lowered to $100 from $103 at BairdMedtronic price target lowered to $100 from $103 at Baird
Bernstein Analyst forecast on MDT
Bernstein
Bernstein
$112
Buy
29.29%
Upside
Reiterated
02/18/26
Analysts Are Bullish on These Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Immunovant (IMVT)
BTIG
Hold
Reiterated
02/18/26
BTIG Sticks to Its Hold Rating for Medtronic (MDT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medtronic

3 Months
xxx
Success Rate
17/23 ratings generated profit
74%
Average Return
+3.88%
initiated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +3.88% per trade.
1 Year
Matt MiksicBarclays
Success Rate
24/36 ratings generated profit
67%
Average Return
+6.51%
reiterated a buy rating 5 days ago
Copying Matt Miksic's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +6.51% per trade.
2 Years
xxx
Success Rate
12/17 ratings generated profit
71%
Average Return
+8.59%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.59% of your transactions generating a profit, with an average return of +8.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
53
45
43
56
50
Hold
27
21
25
32
30
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
80
66
68
88
80
In the current month, MDT has received 50 Buy Ratings, 30 Hold Ratings, and 0 Sell Ratings. MDT average Analyst price target in the past 3 months is 109.80.
Each month's total comprises the sum of three months' worth of ratings.

MDT Financial Forecast

MDT Earnings Forecast

Next quarter’s earnings estimate for MDT is $1.67 with a range of $1.66 to $1.70. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.
Next quarter’s earnings estimate for MDT is $1.67 with a range of $1.66 to $1.70. The previous quarter’s EPS was $1.36. MDT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Sales Forecast

Next quarter’s sales forecast for MDT is $9.66B with a range of $9.61B to $9.71B. The previous quarter’s sales results were $9.02B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.
Next quarter’s sales forecast for MDT is $9.66B with a range of $9.61B to $9.71B. The previous quarter’s sales results were $9.02B. MDT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDT has Performed in-line its overall industry.

MDT Stock Forecast FAQ

What is MDT’s average 12-month price target, according to analysts?
Based on analyst ratings, Medtronic’s 12-month average price target is 109.80.
    What is MDT’s upside potential, based on the analysts’ average price target?
    Medtronic has 26.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDT a Buy, Sell or Hold?
          Medtronic has a consensus rating of Moderate Buy which is based on 11 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Medtronic’s price target?
            The average price target for Medtronic is 109.80. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $125.00 ,the lowest forecast is $86.00. The average price target represents 26.75% Increase from the current price of $86.63.
              What do analysts say about Medtronic?
              Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of MDT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.